Multiple Myeloma Posts on Medivizor
Navigation Menu

Multiple Myeloma Posts on Medivizor

What is the best treatment approach for patients newly diagnosed with multiple myeloma?

What is the best treatment approach for patients newly diagnosed with multiple myeloma?

Posted by on Jun 23, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study investigated which was the best treatment approach before and after stem cell transplantation (SCT) for patients newly diagnosed with multiple myeloma (MM). The results showed that patients’ survival was better with CRD (cyclophosphamide, lenalidomide, and dexamethasone) chemotherapy than with CTD (cyclophosphamide,...

Read More

Long-term results of RVD treatment and risk-based maintenance therapy in newly diagnosed multiple myeloma

Long-term results of RVD treatment and risk-based maintenance therapy in newly diagnosed multiple myeloma

Posted by on Jun 14, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study evaluated long-term outcomes of RVD involving lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Decadron) and risk-based maintenance therapy in patients with newly diagnosed multiple myeloma (MM). The authors found this approach to be beneficial for survival in a large group of patients. Some background RVD...

Read More

Are injections under the skin of daratumumab as effective as intravenous infusions for patients with relapsed or refractory multiple myeloma?

Are injections under the skin of daratumumab as effective as intravenous infusions for patients with relapsed or refractory multiple myeloma?

Posted by on Jun 13, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study examined if subcutaneous (sc) injections of daratumumab (Darzalex) were as effective and safe as intravenous (iv) infusions for patients with relapsed or refractory multiple myeloma (MM). The authors found that sc injections were as effective as iv infusions and caused fewer side effects. Some background Daratumumab...

Read More

Stem cell transplant vs VMP treatment for newly diagnosed multiple myeloma

Stem cell transplant vs VMP treatment for newly diagnosed multiple myeloma

Posted by on Jun 7, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study compared autologous stem cell transplant (SCT) to treatment with the proteasome inhibitor and chemotherapy regimen VMP (bortezomib, melphalan, prednisone) for patients with multiple myeloma (MM). It found that SCT led to better outcomes for the initial treatment of MM. Some background MM is a cancer of the plasma cells, a type...

Read More

Can the addition of bortezomib improve treatment results long-term for patients with multiple myeloma?

Can the addition of bortezomib improve treatment results long-term for patients with multiple myeloma?

Posted by on Jun 6, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study examined if the addition of bortezomib (Velcade) to treatment with lenalidomide (Revlimid) and dexamethasone (Decadron) could improve treatment results long-term for patients with multiple myeloma (MM). The authors found that patients who received bortezomib had a longer survival long-term. Some background...

Read More

Risks of developing kidney toxicity in patients with multiple myeloma treated by carfilzomib

Risks of developing kidney toxicity in patients with multiple myeloma treated by carfilzomib

Posted by on May 31, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study analyzed multiple clinical trials for assessing the effects of carfilzomib (Kyprolis) based treatment on kidney toxicity in patients with multiple myeloma (MM). The main finding was that kidney toxicity was an important side effect of carfilzomib based therapy. Some background Carfilzomib is largely used to treat MM. It is a...

Read More

Managing patients with multiple myeloma during the COVID-19 pandemic

Managing patients with multiple myeloma during the COVID-19 pandemic

Posted by on May 16, 2020 in Multiple Myeloma | 0 comments

In a nutshell The report recommends treatment management for patients with multiple myeloma (MM) during the COVID-19 pandemic. The authors suggested that therapy should be adjusted based on risks. COVID-19 testing should be done before starting therapy. Some background Patients with cancer are generally older and need special care during a pandemic (a...

Read More

Comparing first-line treatments for multiple myeloma

Posted by on Apr 18, 2020 in Multiple Myeloma | 0 comments

In a nutshell This review compared initial treatments for patients with multiple myeloma (MM) that cannot be treated with a transplant. This study found that drug regimens which included the targeted treatments bortezomib or daratumumab had better outcomes. Some background MM is a cancer involving abnormal white blood cells called myeloma cells....

Read More

Long-term outcomes of daratumumab with lenalidomide and dexamethasone in relapsed or unresponsive multiple myeloma

Posted by on Apr 16, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study compared the use of lenalidomide (Revlimid) and dexamethasone (Decadron) alone and with daratumumab (Darzalex) in patients with relapsed or unresponsive multiple myeloma (MM). The study showed that patients receiving all three drugs had better treatment response and survival. Some background MM is a type of cancer that affects...

Read More